Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of NasoShield
NCT03352466Phase 1Completed
- Sponsor
- Altimmune, Inc.
- Start
- Jan 2018
- Primary completion
- May 2019
- Modality
- Prophylactic Vaccines, Nanoparticles, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of nasoshield in anthrax (7 arms), sponsored by Altimmune, Inc. Primary endpoints: Reactogenicity at 14 days and Adverse Events. Started Jan 2018; status: completed.
02
Drugs
nasoshield
03
Conditions
anthrax
Beyond the preview
Go deeper on NCT03352466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03352466.